Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells

European Journal of Cancer Prevention

Volumn 23, Issue 4, 2014, Pages 277-285

  Shin, Ji Ae ^a   Han, Gyoonhee ^b   Kim, Hyun Jung ^c   Kim, Hwan Mook ^d   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Gachon University   (South Korea)

Author keywords

apoptosis; Bid; Bim; breast cancer; histone deacetylase inhibitor; Ky2; specificity protein 1

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; KY 2; MESSENGER RNA; MITHRAMYCIN; MITHRAMYCIN A; PROTEIN BID; PROTEINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VORINOSTAT; CYCLOPEPTIDE; KY-2 CYCLIC PEPTIDE; SP1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME RELEASE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 231 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFECTS; DRUG THERAPY; FEMALE; GENETICS; METABOLISM; SECRETION (PROCESS); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPREVENTION; CYTOCHROMES C; DRUG THERAPY; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; PEPTIDES, CYCLIC; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR;

EID: 84901997469     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000041     Document Type: Article

References (45)

1. Amiri-Kordestani L, Tan AR, Swain SM (2012). Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs 21:217-225
2. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P, et al. (2001). Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome 12:163-168
3. Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A (2007). Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 8:388-400
4. Choi ES, Shim JH, Jung JY, Kim HJ, Choi KH, Shin JA, et al. (2011). Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 102:742-748
5. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in earlystage breast cancer. Oncologist 9:606-616
6. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, et al. (2004). The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3:1397-1402
7. Dokmanovic M, Clarke C, Marks PA (2007). Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 5:981-989
8. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, et al. (1999). Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274:32099-32107
9. Duan H, Heckman CA, Boxer LM (2005). Histone deacetylase inhibitors downregulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608-1619
10. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH, et al. (2010). The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 9:1349-1360
11. Ellis L, Pili R (2010). Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3:2411-2469
12. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, et al. (2013). Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors. Heart 99:634-639
13. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, et al. (2008). Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381
14. Furumai R, Ito A, Ogawa K, Maeda S, Saito A, Nishino N, et al. (2011). Histone deacetylase inhibitors block nuclear factor-kappaB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci 102:1081-1087
15. Gillenwater AM, Zhong M, Lotan R (2007). Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6:2967-2975
16. Higgins MJ, Baselga J (2011). Targeted therapies for breast cancer. J Clin Invest 121:3797-3803
17. Huang L, Pardee AB (2000). Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6:849-866
18. Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, et al. (2012). Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One 7:e43645
19. Kaczynski J, Cook T, Urrutia R (2003). Sp1- And Kruppel-like transcription factors. Genome Biol 4:206
20. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931. (Pubitemid 46218695)
21. Kim DH, Kim M, Kwon HJ (2003). Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110-119. (Pubitemid 36836262)
22. Krusche CA, Wulfing P, Kersting C, Vloet A, Böcker W, Kiesel L, et al. (2005). Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res Treat 90:15-23
23. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010). Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107:14639-14644
24. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, et al. (2009). High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9:395
25. Li L, Davie JR (2010). The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192:275-283
26. Ring A, Dowsett M (2004). Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658
27. Ropero S, Esteller M (2007). The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19-25
28. Rosato RR, Almenara JA, Grant S (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63:3637-3645
29. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, et al. (2003). Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 100:4281-4286
30. Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB, Kim CY (2006). SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 237:143-154
31. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, et al. (2007). Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73:1901-1909
32. Shim JH, Shin JA, Jung JY, Choi KH, Choi ES, Cho NP, et al. (2011). Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev 20:102-111
33. Shin JA, Shim JH, Jeon JG, Choi KH, Choi ES, Cho NP, Cho SD (2011). Apoptotic effect of Polygonum cuspidatum in oral cancer cells through the regulation of specificity protein 1. Oral Dis 17:162-170
34. Shin JA, Kim JJ, Choi ES, Shim JH, Ryu MH, Kwon KH, et al. (2012). In vitro apoptotic effects of methanol extracts of Dianthus chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells. Head Neck 35:992-998
35. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics 2012. CA Cancer J Clin 62:10-29
36. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM (2010). The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 1:596-605
37. Takahashi O, Okinaga T, Iwanaga K, Habu M, Ariyoshi W, Tominaga K, et al. (2011). Novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction in oral squamous cell carcinoma. J Biophys Chem 2:215-221
38. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, et al. (2001). Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29:3006-3011
39. Ulrich E, Kauffmann-Zeh A, Hueber AO, Williamson J, Chittenden T, Ma A, Evan G (1997). Gene structure, cDNA sequence, and expression of murine Bak, a proapoptotic Bcl-2 family member. Genomics 44:195-200
40. Van Delft MF, Huang DC (2006). How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16:203-213
41. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, et al. (2010). Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9:275
42. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al. (2008a). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10:1021-1027
43. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. (2008b). Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 9:139-148
44. Witt O, Deubzer HE, Milde T, Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277:8-21
45. Yu HJ, Shin JA, Nam JS, Kang BS, Cho SD (2013). Apoptotic effect of dibenzylideneacetone on oral cancer cells via modulation of specificity protein 1 and Bax. Oral Dis 19:767-774